Next 10 |
2024-07-26 11:06:38 ET More on Geron Geron: Innovative Rytelo Enters A Challenging MDS Market Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron Corporation (GERN) Q1 2024 Earnings Call Transcript Biggest stock movers today: TSLA, V, DB, ...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
2024-07-24 06:53:38 ET Geron ( NASDAQ: GERN ) shares plunged around 7% premarket on Wednesday after the biopharmaceutical company said Anil Kapur, its executive vice president, corporate strategy and chief commercial officer, will depart on Aug. 31, 2024 to pursue other inte...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...
2024-07-11 14:23:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout....
2024-06-13 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors can’t figure out how to invest in penny stocks because they don’t know what to look for. Some penny stocks are companies in beginning phases that have yet to sc...
2024-06-11 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to ...
2024-06-10 14:00:11 ET Corinne Jenkins from Goldman Sachs issued a price target of $6.00 for GERN on 2024-06-10 11:59:00. The adjusted price target was set to $6.00. At the time of the announcement, GERN was trading at $4.945. The overall price target consensus is at $5....
2024-06-10 10:25:57 ET More on Geron Geron: Innovative Rytelo Enters A Challenging MDS Market Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron jumps as FDA approves lead asset for blood cancer Geron Corporation (GERN) Q1 2024 Earnings C...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...